| Abstract: | Inhibitors of platelet aggregation (“anti‐platelets”) constitute a remarkably heterogeneous family of drugs, with regard to both chemistry and biochemistry. The rather uncommon diversity and the continuing search for new anti‐platelet drugs results from the particular requirements: high efficacy associated with good tolerability especially during long‐term treatment, marginal side effects and easy administration. Sophisticated structural modifications to lead compounds are employed to meet these requirements and improve bio‐availability and efficacy. While thromboxane synthesis and ADP receptors are currently the most prominent targets of anti‐platelet drugs, a number of other promising targets are now evaluated and new drugs are on the verge. |
